Ruffelli M - Search Results

1

Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid.

Frezzolini A, Teofoli P, Cianchini G, Barduagni S, Ruffelli M, Ferranti G, Puddu P, De Pita O. Frezzolini A, et al. Among authors: ruffelli m. Eur J Dermatol. 2002 Jan-Feb;12(1):27-31. Eur J Dermatol. 2002. PMID: 11809592

2

The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris.

Sinistro A, Calabresi V, Lupi F, Sera F, Frezzolini A, Ruffelli M, De Pità O, Camaioni D, Cianchini G, Di Zenzo G. Sinistro A, et al. Among authors: ruffelli m. Eur J Dermatol. 2015 Nov-Dec;25(6):578-85. doi: 10.1684/ejd.2015.2652. Eur J Dermatol. 2015. PMID: 26552329

3

T-helper 2 involvement in the pathogenesis of bullous pemphigoid: role of soluble CD30 (sCD30).

De Pitá O, Frezzolini A, Cianchini G, Ruffelli M, Teofoli P, Puddu P. De Pitá O, et al. Among authors: ruffelli m. Arch Dermatol Res. 1997 Nov;289(12):667-70. doi: 10.1007/s004030050259. Arch Dermatol Res. 1997. PMID: 9452886

4

Interleukin-16 expression and release in bullous pemphigoid.

Frezzolini A, Cianchini G, Ruffelli M, Cadoni S, Puddu P, De Pità O. Frezzolini A, et al. Among authors: ruffelli m. Clin Exp Immunol. 2004 Sep;137(3):595-600. doi: 10.1111/j.1365-2249.2004.02570.x. Clin Exp Immunol. 2004. PMID: 15320912 Free PMC article.

5

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.

Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Cianchini G, et al. Among authors: ruffelli m. Arch Dermatol. 2007 Aug;143(8):1033-8. doi: 10.1001/archderm.143.8.1033. Arch Dermatol. 2007. PMID: 17709662 Review.

6

Soluble CD30 in pediatric patients with atopic dermatitis.

Frezzolini A, Paradisi M, Ruffelli M, Cadoni S, De Pità O. Frezzolini A, et al. Among authors: ruffelli m. Allergy. 1997 Jan;52(1):106-9. doi: 10.1111/j.1398-9995.1997.tb02554.x. Allergy. 1997. PMID: 9062638

7

Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel serological marker of disease activity.

Frezzolini A, Paradisi M, Zaffiro A, Provini A, Cadoni S, Ruffelli M, De Pità O. Frezzolini A, et al. Among authors: ruffelli m. Allergy. 2002 Sep;57(9):815-20. doi: 10.1034/j.1398-9995.2002.23687.x. Allergy. 2002. PMID: 12169178

8

Psoriasis: comparison of immunological markers in patients with acute and remission phase.

De Pità O, Ruffelli M, Cadoni S, Frezzolini A, Biava GF, Simom R, Bottari V, De Sanctis G. De Pità O, et al. Among authors: ruffelli m. J Dermatol Sci. 1996 Nov;13(2):118-24. doi: 10.1016/s0923-1811(96)00517-8. J Dermatol Sci. 1996. PMID: 8953411

9

Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention.

Bottari V, Frezzolini A, Ruffelli M, Puddu P, Fontana L, De Pità O. Bottari V, et al. Among authors: ruffelli m. Allergy. 1999 May;54(5):507-10. doi: 10.1034/j.1398-9995.1999.00958.x. Allergy. 1999. PMID: 10380784 Clinical Trial.

10

Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus.

Puddu P, De Pità O, Ruffelli M, Bellucci AM, Girardelli CR, Galeazzi M, Marcolongo R. Puddu P, et al. Among authors: ruffelli m. Arthritis Rheum. 1996 Apr;39(4):704-5. doi: 10.1002/art.1780390426. Arthritis Rheum. 1996. PMID: 8630125 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters